Drug intelligence / Profile preview

carbon-14-labeled carboplatin

Development stage: Unknown
Lead developer: UC Davis
Modality: Small Molecules, Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics
Administration: Intravenous

Overview

Carbon-14-labeled carboplatin is a radiolabeled version of carboplatin used primarily for research purposes to study the pharmacokinetics, metabolism, and distribution of carboplatin in the body. Carboplatin is an organoplatinum antineoplastic alkylating agent that works by cross-linking DNA, preventing DNA strands from separating for synthesis or transcription, and inducing mutations. It has a similar mechanism of action to cisplatin but with a different toxicity profile, particularly causing less nephrotoxicity, ototoxicity, and neurotoxicity but more myelosuppression.

Targets

DNA

Beyond the preview

Go deeper on carbon-14-labeled carboplatin.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on carbon-14-labeled carboplatin.

Explore the full profile